US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> Alterations
AstraZeneca
Asma Dilawari; James Buturla; Christy Osgood; Xin Gao; Wei Chen; Tiffany K Ricks; Timothy Schaefer; Sreedevi Avasarala; Francisca Reyes Turcu; Anand Pathak; Shyam Kalavar; Vishal Bhatnagar; Justin Collazo; Nam Atiqur Rahman; Bronwyn Mixter; Shenghui Tang; Richard Pazdur; Paul Kluetz; Laleh Amiri-Kordestani